CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive advice
EMA's human medicines committee recommended two insulin aspart biosimilars and baxdrostat for hypertension, and adopted a communication on tirzepatide and oral contraceptives.

At a glance
- At its 9-12 November 2026 meeting, the CHMP adopted positive opinions for two insulin aspart biosimilars, Garzulys and Donrafylix, for diabetes mellitus from 1 year of age. Both are pending a European Commission decision.
- The CHMP also recommended Baxfendy (baxdrostat) for hypertension in adults. It is pending a European Commission decision.
- A communication to healthcare professionals says limited information is available on how tirzepatide affects oral contraceptives. It advises women using an oral contraceptive to add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, or to switch to a non-oral method.
The study
This report is based on the meeting highlights of the Committee for Medicinal Products for Human Use (CHMP), the human medicines committee of the European Medicines Agency (EMA). The meeting took place on 9-12 November 2026, and the highlights were published on 13 November 2026. This is a regulatory news release, not a clinical study. The committee recommended seven new medicines and 11 extensions of indication. Only the items relevant to diabetes, obesity and related care are covered here.
What they found
Insulin aspart biosimilars. The CHMP adopted positive opinions for two biosimilar medicines, Garzulys and Donrafylix. Both contain insulin aspart. They are intended for diabetes mellitus in adults, adolescents and children aged 1 year and above. The applicants are Sciencepharma Sp. z o.o. (Garzulys) and Kuraci (Donrafylix). Both are pending a European Commission (EC) decision.
Baxdrostat. The CHMP recommended a marketing authorisation for Baxfendy (baxdrostat) for the treatment of insufficiently controlled hypertension in adults. The applicant is AstraZeneca AB. The EC decision is pending.
Tirzepatide and oral contraceptives. The CHMP adopted a direct healthcare professional communication (DHPC) about the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives. The DHPC reminds professionals that contraception is recommended for women who can become pregnant and are using Mounjaro. It states that limited information is available on the effect of tirzepatide on the pharmacokinetics and efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes. Women using an oral contraceptive are now advised to do one of two things. They can add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Or they can switch to a non-oral method of contraception.
How much weight to give it
A CHMP opinion is a recommendation. The EC decision is still pending for all the new medicines named above. The highlights do not report any trial data, efficacy results or safety results for the insulin aspart biosimilars or for baxdrostat. They also do not describe the evidence behind the biosimilar opinions. The tirzepatide communication is a regulatory safety message. EMA itself describes the information on the interaction as limited, so the size of any effect on contraceptive reliability is not given in the highlights.
For your clinic
No change in practice follows from the new opinions until the EC decisions are made. Even then, availability in India would need to be checked separately. Before using any new insulin aspart biosimilar, read the full assessment and your local prescribing information. For women who can become pregnant and are taking or considering tirzepatide, the DHPC is a prompt to raise contraception in the consultation. Read the full DHPC and the current product information before changing any advice.
Source
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
European Medicines Agency news. European Medicines Agency news. 13 November 2026
Cite this report: Diabesity Rounds. CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive advice. 2026. doi:10.5281/zenodo.24236987
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on approvals and safety
- Guidance on immunotherapy for children with new-onset stage 3 type 1 diabetesGuideline · 12 November 2026
- FDA adds NAION eye warning to labels of all GLP-1 receptor agonistsRegulatory · 10 November 2026
- StatStrip Gen 2.0 hospital glucose meter recall: results may go to wrong patientRegulatory · 31 October 2026
- CDSCO expert committee: Phase III trial of degludec/aspart mix recommendedRegulatory · 31 October 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.